Evaluating the cost-effectiveness of treatment with third-generation cephalosporins.
Spreadsheet computer software was used to compare the estimated global treatment costs of the third-generation cephalosporins, cefotaxime and ceftriaxone, in the management of pneumonia using treatment schedules taken from current studies. Included in the analysis were not only acquisition costs, but also costs that contribute to total expenses for a course of treatment, such as those of (a) preparation and administration (disposable supplies, nursing, and pharmacy time), (b) projected laboratory costs to monitor for hypoprothrombinemia, and (c) complication costs (diarrhea, superinfection, pseudocholelithiasis, and so on). The cost analysis was performed using United States trial-derived factors. Where published cost factors were not available, reasonable estimates were sought. Our analysis indicates that cefotaxime therapy may be less costly than ceftriaxone therapy in the dosage schedules used in these clinical studies and routine clinical practice.
Gladen
H E
HE
University of California, San Francisco/Fresno, California.
D002439:Cefotaxime / Q000191:economics* / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006801:Humans; D012984:Software
D002443:Ceftriaxone; D002439:Cefotaxime